A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
Protocol: SWOG – S2200 SCHEMA S2200 Please Note: Below is partial eligibility, for full eligibility requirements, please contact Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you! Eligibility: Participants must have a histologically confirmed diagnosis of metastatic papillary renal cell carcinoma (PRCC), either type 1 or type 2. (NOTE: A designation […]